Tvardi Therapeutics, Inc. (formerly Cara Therapeutics) is a clinical-stage biopharmaceutical company based in Sugar Land, Texas. It is developing oral small-molecule therapies that target STAT3, a key protein tied to immune issues, inflammation, fibrosis, and cancer cell survival. The lead programs include TTI-101 in a Phase 1b/2 trial for hepatocellular carcinoma and TTI-109, a prodrug aimed at better gastrointestinal tolerability while keeping the same mechanism. As a pre-revenue biotech, TVRD moves largely on clinical updates rather than sales figures.
Over the past 30 days, TVRD gained about 10%, climbing from roughly $1.07 in mid-October to around $1.18 at the latest close. The route was uneven, with a dip to near $0.79 in late October followed by a strong volume-driven rally above $1.40 in early November and then some retracement. This short-term lift stands in contrast to the broader picture, where the stock fell about 38% over the trailing quarter after giving back gains from its July surge on Phase 1 data for TTI-109.
Several developments helped support the recent move. On November 13, the company posted third-quarter 2026 results showing a net loss of $6.1 million, or $0.48 per share, which beat the consensus estimate of about $0.57 per share. Management noted that its $22.3 million cash position should fund operations into the third quarter of 2027 and flagged the expected early-2027 topline readout for TTI-101 in HCC. Analyst coverage added to the tone, with Chardan starting at Buy and an $8 target in late October, JonesTrading holding Buy with a $10 target, and H.C. Wainwright reiterating Buy at $9. The firm also pointed to new preclinical data in the International Journal of Molecular Sciences on STAT3 inhibition in ulcerative colitis, showing roughly eightfold higher colon tissue exposure than plasma in a chronic model. The early-November volume spike appeared to reflect positioning ahead of these updates.
The longer-term pullback stems from pipeline adjustments, financing needs, and typical small-cap biotech pressures. After the July rally on positive TTI-109 Phase 1 results, shares eased as investors factored in execution risks, an earlier Phase 2 miss for TTI-101 in idiopathic pulmonary fibrosis, and the shift toward HCC and inflammatory indications. An at-the-market equity offering in the third quarter and the need for more capital to advance TTI-109 also weighed on sentiment, as did earlier price-target revisions by analysts.
The main near-term focus remains the topline data from the Phase 1b/2 REVERT LIVER CANCER study of TTI-101 in hepatocellular carcinoma, due in early 2027. Progress on TTI-109, including IND clearance and movement toward ulcerative colitis trials, will also matter and will depend on securing additional funding. Capital position and any further financing activity stay important given the pre-revenue stage. Sector-wide biotech sentiment, interest rates, and competitive moves in STAT3 or liver-cancer therapies represent additional variables to track. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
When reviewing names like TVRD, I find it helpful to look at systematic approaches alongside traditional research. Tickeron’s Trending AI Robots page highlights a selection of top-performing automated strategies from a larger set of AI-driven bots that trade thousands of tickers. Each robot differs in strategy, timeframe, and metrics, giving traders options that can fit different styles and risk levels. Exploring these can provide another angle when analyzing clinical-stage companies and their catalysts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TVRD declined for three days, in 315 of 348 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The 10-day RSI Indicator for TVRD moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 24 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 55 cases where TVRD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
TVRD moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
TVRD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TVRD entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TVRD as a result. In 64 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for TVRD just turned positive on October 15, 2026. Looking at past instances where TVRD's MACD turned positive, the stock continued to rise in 32 of 36 cases over the following month. The odds of a continued upward trend are 89%.
Following a +64.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVRD advanced for three days, in 185 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.524) is normal, around the industry mean (3.498). P/E Ratio (-0.334) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. TVRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TVRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology